10-K Filing

ENZON PHARMACEUTICALS, INC. CIK: 727510 FY 2020

Filing Information

Form Type	10-K
Accession Number	`0001104659-21-026712`
Period End Date	20201231
Filing Date	20210223
Fiscal Year	2020
Fiscal Period	FY
XBRL Instance	enzn-20201231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 48 Income Statement 24 Cash Flow Statement 29 Stockholders Equity 10

Balance Sheet 48 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$48.14M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.45M	USD	Point-in-time
Royalty receivable	`MilestoneReceivableOnRoyaltiesCurrent`	$31.00K	USD	Point-in-time
Refundable tax credits receivable, current portion	`IncomeTaxesReceivable`	$485.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$59.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$62.00K	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Total current assets	`AssetsCurrent`	$5.99M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$48.23M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	2.96M	shares	Point-in-time
Refundable tax credits receivable, net of current portion	`IncomeTaxesReceivableNoncurrent`	$485.00K	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	2.96M	shares	Point-in-time
Total assets	`Assets`	$6.48M	USD	Point-in-time
Total assets	`Assets`	$48.23M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	170.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	170.00M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$324.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$302.00K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	44.21M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	74.21M	shares	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$110.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$99.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$423.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	44.21M	shares	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$412.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	74.21M	shares	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock - $0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at December 31, 2020 and 2019	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock - $0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at December 31, 2020 and 2019	`PreferredStockValue`	-	USD	Point-in-time
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at December 31, 2020 and 44,214,603 at December 31, 2019	`CommonStockValue`	$442.00K	USD	Point-in-time
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at December 31, 2020 and 44,214,603 at December 31, 2019	`CommonStockValue`	$742.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$78.01M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$75.69M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-70.08M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-71.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.05M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$14.99M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$7.36M	USD	Point-in-time
Total liabilities, mezzanine equity and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$48.23M	USD	Point-in-time
Total liabilities, mezzanine equity and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$6.48M	USD	Point-in-time

Income Statement 24 line items

Line Item	Tag	Value	Unit	Period
Royalties and milestones, net	`RoyaltyRevenueAndMilestones`	$207.00K	USD	Annual
Royalties and milestones, net	`RoyaltyRevenueAndMilestones`	$52.00K	USD	Annual
Total revenues	`Revenues`	$207.00K	USD	Annual
Total revenues	`Revenues`	$52.00K	USD	Annual
General and administrative	`OtherGeneralAndAdministrativeExpense`	$1.36M	USD	Annual
General and administrative	`OtherGeneralAndAdministrativeExpense`	$1.18M	USD	Annual
Total operating expenses	`OperatingExpenses`	$1.36M	USD	Annual
Total operating expenses	`OperatingExpenses`	$1.18M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-973.00K	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-1.30M	USD	Annual
Other income	`OtherNonoperatingIncome`	$1.00K	USD	Annual
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-973.00K	USD	Annual
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.30M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$6.00K	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$7.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-979.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-1.31M	USD	Annual
Dividends on Series C preferred stock	`PreferredStockDividendsIncomeStatementImpact`	$460.00K	USD	Annual
Net loss available to common shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-1.77M	USD	Annual
Net loss available to common shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-979.00K	USD	Annual
Basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	Annual
Basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.03	USD	Annual
Basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	44.22M	shares	Annual
Basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	51.10M	shares	Annual

Cash Flow Statement 29 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-979.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-1.31M	USD	Annual
Decrease in milestone receivable	`IncreaseDecreaseInMilestonesReceivable`	$-7.00M	USD	Annual
(Increase) decrease in other current assets and accounts receivable	`IncreaseDecreaseInOtherOperatingAssets`	$28.00K	USD	Annual
(Increase) decrease in other current assets and accounts receivable	`IncreaseDecreaseInOtherOperatingAssets`	$-8.00K	USD	Annual
Decrease in refundable tax credit receivable	`IncreaseDecreaseInLongTermReceivablesCurrent`	$-970.00K	USD	Annual
Decrease in refundable tax credit receivable	`IncreaseDecreaseInLongTermReceivablesCurrent`	$-970.00K	USD	Annual
Decrease in accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$-115.00K	USD	Annual
Decrease in accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$-22.00K	USD	Annual
Increase in accrued expenses and other current liabilities	`IncreaseDecreaseInOtherAccruedLiabilities`	$21.00K	USD	Annual
Increase in accrued expenses and other current liabilities	`IncreaseDecreaseInOtherAccruedLiabilities`	$11.00K	USD	Annual
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$6.91M	USD	Annual
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-380.00K	USD	Annual
Payment of offering costs	`PaymentsOfStockIssuanceCosts`	$524.00K	USD	Annual
Proceeds from rights offering	`ProceedsFromIssuanceOfCommonStock`	$43.60M	USD	Annual
Common stock dividends	`PaymentsOfDividendsCommonStock`	$5.31M	USD	Point-in-time
Common stock dividends	`PaymentsOfDividendsCommonStock`	$7.96M	USD	Annual
Common stock dividends	`PaymentsOfDividendsCommonStock`	-	USD	Annual
Common stock dividends	`PaymentsOfDividendsCommonStock`	$2.65M	USD	Point-in-time
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-7.96M	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$43.08M	USD	Annual
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.05M	USD	Annual
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$42.70M	USD	Annual
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.50M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.45M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$48.14M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.50M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.45M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$48.14M	USD	Point-in-time

Stockholders Equity 10 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$6.05M	USD	Point-in-time
Balance	`StockholdersEquity`	$14.99M	USD	Point-in-time
Balance	`StockholdersEquity`	$7.36M	USD	Point-in-time
Net loss	`NetIncomeLoss`	$-979.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-1.31M	USD	Annual
Preferred stock dividend accumulation	`DividendsCommonStockStock`	$460.00K	USD	Annual
Preferred stock dividend accumulation	`DividendsCommonStockStock`	$7.96M	USD	Annual
Balance	`StockholdersEquity`	$6.05M	USD	Point-in-time
Balance	`StockholdersEquity`	$14.99M	USD	Point-in-time
Balance	`StockholdersEquity`	$7.36M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.